Last reviewed · How we verify

inhalation of afatinib dimaleate

Petrov, Andrey · Phase 1 active Biologic

inhalation of afatinib dimaleate is a Biologic drug developed by Petrov, Andrey. It is currently in Phase 1 development. Also known as: Afatinib Dimaleate, BIBW2992 Dimaleate.

At a glance

Generic nameinhalation of afatinib dimaleate
Also known asAfatinib Dimaleate, BIBW2992 Dimaleate
SponsorPetrov, Andrey
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about inhalation of afatinib dimaleate

What is inhalation of afatinib dimaleate?

inhalation of afatinib dimaleate is a Biologic drug developed by Petrov, Andrey.

Who makes inhalation of afatinib dimaleate?

inhalation of afatinib dimaleate is developed by Petrov, Andrey (see full Petrov, Andrey pipeline at /company/petrov-andrey).

Is inhalation of afatinib dimaleate also known as anything else?

inhalation of afatinib dimaleate is also known as Afatinib Dimaleate, BIBW2992 Dimaleate.

What development phase is inhalation of afatinib dimaleate in?

inhalation of afatinib dimaleate is in Phase 1.

Related